论文部分内容阅读
采用国产奈替米星和阿米卡星随机对照治疗各种类型急性细菌性感染２０４例，奈替米星７７例与阿米卡星７６例作随机对照，开放试验５１例。治愈率和有效率分别为７５．３％、９６．１％；６７．１％、９３．４％；８６．３％、９４．１％（Ｐ＞０．１，Ｐ＞０．２５）。细菌清除率分别为９０．７％；８８．０％；９３．０％（Ｐ＞０．０５）。不良反应发生率分别为５．１％、３．９％、３．９％（Ｐ＞０．５）。试验组和对照组临床疗效、细菌学疗效及不良反应均无显著性差异，奈替米星和阿米卡星纸片敏试敏感率相似，奈替米星对葡萄球菌的ＭＩＣ比阿米卡星略低，对链球菌两者相似或奈替米星略低，对革兰氏阴性细菌两者相似或阿米卡星略低，头孢噻肟对革兰氏阳性及阴性细菌抗菌活性比较强，庆大霉素较弱。８名健康自愿受试者静脉滴注或肌肉注射１００ｍｇ奈替米星，血峰浓度分别为１３．１２及７．６ｍｇ／Ｌ，半衰期（Ｔ１／２β）分别为３．２及２．８ｈ，分布容积分别为１５．４７及１１．５８ｈｍｇ／Ｌ，８ｈ后血药浓度分别为０．８８和０．８５ｍｇ／Ｌ。尿药浓度分别为１３．６４及１４．７９ｍｇ／Ｌ。血药浓度均超过绝大多数细菌的最低抑菌浓度，故获得较好临床疗效。
204 cases of various types of acute bacterial infections were treated with domestic netilmicin and amikacin. 77 cases were given netilmicin and 76 amikacin were randomized to open trial. The cure rates and effective rates were 75.3%, 96.1%, 67.1%, 93.4%, 86.3%, 94.1% (P> 0.1, P> 0.25). Bacterial clearance rates were 90.7%, 88.0% and 93.0%, respectively (P> 0.05). Adverse reactions were 5.1%, 3.9%, 3.9% (P> 0.5). The clinical efficacy, bacteriological efficacy and adverse reactions of the experimental group and the control group showed no significant difference. The susceptibility rates of netilmicin and amikacin were similar to that of the sensitive test paper. The effect of netilmicin on staphylococcal MIC Slightly lower for star, slightly lower for streptococci or slightly lower for netilmicin, slightly more similar for Gram-negative bacteria or amikacin, cefotaxime more strongly against Gram-positive and -negative bacteria , Gentamicin weaker. Eight healthy volunteers received intravenous infusion or intramuscular injection of 100 mg netilmicin with peak plasma concentrations of 13.12 and 7.6 mg / L, respectively, with half-life (T1 / 2β) of 3.2 and 2.8 h, respectively. The volume of distribution was 15.47 and 11.58hmg / L, respectively. After 8h, the plasma concentrations were 0.88 and 0.85mg / L, respectively. Urine concentrations were 13.64 and 14.79 mg / L, respectively. Blood concentrations exceed the minimum inhibitory concentration of most bacteria, so get better clinical efficacy.